Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047432 | 1.00 | CYP2D6 (0.33) | CYP2D6ADORA2A | |
| SCHEMBL23265542 | 0.86 | CYP2D6 (0.39) | CYP2D6 | |
| SCHEMBL2738324 | 0.86 | CYP2D6 (0.39) | CYP2D6 | |
| SCHEMBL25004839 | 0.86 | CYP2D6 (0.39) | CYP2D6 | |
| SCHEMBL2739922 | 0.82 | HSD11B1 (0.34) | CYP2D6ADORA2A | |
| SCHEMBL4473518 | 0.77 | LIPE (0.33) | CYP2D6 | |
| SCHEMBL24317895 | 0.77 | — | — | |
| SCHEMBL12030637 | 0.76 | — | — | |
| SCHEMBL23265545 | 0.75 | — | — | |
| SCHEMBL14524120 | 0.75 | HRH3 (0.36) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | OXFORD FINANCE LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8853423-B2 | Indane estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8703810-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130137746-A1 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8268862-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110152254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | CYP2D6 4452/4885ADORA2A 2083/4885 |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | CYP2D6 4727/4885ADORA2A 3985/4885 |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | MKI67, CCNA1, CCNT1 | CYP2D6 451/4885ADORA2A 1759/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CYP2D6 4302/4885ADORA2A 4217/4885 |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | CYP2D6 836/4885ADORA2A 402/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP2D6 4304/4885ADORA2A 4133/4885 |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | CYP2D6 1807/4885ADORA2A 2255/4885 |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | STAT5A, STAT5B, STAT3 | CYP2D6 4671/4885ADORA2A 3933/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CYP2D6 3561/4885ADORA2A 4546/4885 |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | CYP2D6 869/4885ADORA2A 409/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | CYP2D6 4452/4885ADORA2A 2083/4885 |
| US-20130137746-A1 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | CYP2D6 600/4885ADORA2A 508/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | CYP2D6 2301/4885ADORA2A 3542/4885 |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | CYP2D6 1807/4885ADORA2A 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.